Immunoassay Market Size, Share & Trends Analysis Report By Product (Reagents & Kits, Analyzers, Software & Services), By Technology (ELISA, Rapid Tests, Western Blotting, Radioimmunoassay, Others), By Specimen (Blood, Saliva, Urine, Others), By Application (Infectious Diseases, Endocrinology, Oncology, Cardiology, Autoimmune Disorders, Allergy Diagnostics, Toxicology, Others), By End-User (Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, CROs, Blood Banks, Research Laboratories, Home Care Settings, Others), By Region (North America, Europe, APAC, Middle East and Africa, LATAM), Forecasts, 2026-2034

Last Updated: November 05, 2026 | Author: Debashree Bora | Format:

Immunoassay Market Size, Share & Growth Analysis

The global immunoassay market size was valued at USD 28.29 billion in 2025 and is projected to grow from USD 29.60 billion in 2026 to USD 42.55 billion by 2034, registering a CAGR of 4.64% during the forecast period (2026–2034). North America dominated the immunoassay market with a share of 39.5% in 2025.

The immunoassay focuses on the development and supply of diagnostic tests and analytical solutions that use antigen-antibody interactions to detect and measure specific substances in biological samples. These technologies are widely used in clinical diagnostics, pharmaceutical research, disease screening, and infectious disease testing to support accurate and timely medical analysis.

Immunoassay Market Key Takeaways

Global Market Size & Growth

2025 Market Size
USD 28.29 Billion
2026 Market Size
USD 29.60 Billion
2034 Projected Market Size
USD 42.55 Billion
Forecast Period
2026–2034
Base Year
2025
Market CAGR (2026–2034)
4.64%

Regional Insights

Largest Regional Market (2025)
North America
North America Market Share (2025)
39.5%
Fastest-growing Region
Asia Pacific
Asia Pacific CAGR (2026–2034)
9.35%

Segment Insights

By Product
Fastest-growing Segment
Rapid Test Reagent & Kits
CAGR 8.7% (2026–2034)
By Technology
Leading Segment
ELISA
Market Share in 2025 44.5%
By Specimen
Fastest-growing Segment
Saliva
CAGR 8.75% (2026–2034)
By Application
Leading Segment
Infectious diseases
Market Share in 2025 31.8%
By End-User
Fastest-growing Segment
Home Care Setting
CAGR 9.05% (2026–2034)
Immunoassay Market Size , Share and Growth Forecast 2026-2034

Download a Free SampleTo learn more about this report.

Immunoassay Market Dynamics

01

Prevalence of Infectious and Chronic Diseases Drives Market

The high prevalence of infectious and chronic diseases is supporting demand for immunoassay-based diagnostic testing across healthcare facilities. Conditions such as cancer, HIV, hepatitis, and cardiovascular disorders require regular biomarker detection and disease monitoring. For instance, immunoassay tests help detect HIV antibodies, hepatitis antigens, and cardiac troponin levels in patient samples. This clinical requirement encourages hospitals and diagnostic laboratories to maintain adequate supplies of immunoassay kits and reagents. The higher volume of diagnostic testing supports product demand and creates opportunities for manufacturers to strengthen their supply capabilities.

02

Need for Early and Accurate Disease Diagnosis Boosts Market Demand

Greater attention to early disease diagnosis is supporting the use of immunoassay techniques for detecting specific biomarkers and health conditions. These tests help healthcare professionals identify hormonal imbalances, infections, and other medical conditions through blood and urine samples. For instance, pregnancy tests, thyroid function assessments, and cardiac marker tests use immunoassay-based methods for clinical evaluation. The need for timely and accurate diagnostic results encourages healthcare facilities to increase their use of immunoassay testing solutions. This requirement supports demand for specialized testing kits, reagents, and diagnostic products.

03

Impact Analysis of Key Drivers in Immunoassay Market

DriversMarket Impact

Prevalence of Infectious and Chronic Diseases

The high prevalence of cancer, cardiovascular disorders, HIV, and hepatitis increases the need for immunoassay-based diagnostic testing. This supports demand for testing kits, reagents, and diagnostic solutions across healthcare facilities.

Need for Early and Accurate Disease Diagnosis

Greater focus on early disease identification supports the use of immunoassay tests for detecting hormones, proteins, antibodies, and disease biomarkers. This encourages regular testing across hospitals, clinics, and diagnostic laboratories.

Point-of-Care Diagnostic Testing

The preference for rapid diagnostic results in emergency departments, clinics, and remote healthcare settings supports demand for point-of-care immunoassay products.

Wider Availability of Clinical Diagnostic and Laboratory Services

The broader presence of diagnostic laboratories, pathology centers, and hospital testing facilities increases the utilization of immunoassay kits and reagents.

Need for Hormone and Fertility Testing

The rising use of hormone assessments for thyroid disorders, pregnancy confirmation, and reproductive health evaluations supports demand for immunoassay-based testing solutions.

01

High Costs of Advanced Immunoassay Instruments and Testing

High costs of advanced immunoassay analyzers, specialized reagents, and regular equipment maintenance increase the financial burden on diagnostic laboratories and healthcare facilities. These expenses make it difficult for smaller laboratories and healthcare centers to invest in automated testing systems and expand their diagnostic capacity. Such cost barriers limit instrument adoption, restrict access to immunoassay testing, and slow market growth, particularly in cost-sensitive regions.

02

Interference and False-Positive or False-Negative Results

Interference from cross-reacting substances, heterophilic antibodies, and other biological components can affect immunoassay accuracy and produce misleading test results. These inaccuracies may require repeat testing or confirmation through alternative diagnostic methods, increasing testing time and healthcare costs. Concerns about result reliability reduce clinical confidence and limit the adoption of immunoassay techniques in applications that require high diagnostic accuracy.

03

Impact Analysis of Key Restraints in Immunoassay Market

RestraintsMarket Impact

High Costs of Advanced Immunoassay Instruments and Testing

Expensive analyzers, reagents, and maintenance requirements increase diagnostic costs and limit adoption among smaller laboratories and healthcare facilities.

Interference and False-Positive or False-Negative Results

Cross-reactivity, interfering substances, and variations in antibody performance can affect test accuracy and create challenges in clinical decision-making.

Limited Standardization Across Immunoassay Platforms

Differences in assay formats, calibration methods, and reagent performance create inconsistent results and complicate comparisons across laboratories.

Shortage of Skilled Laboratory Professionals

Limited availability of trained technicians and laboratory specialists restricts efficient instrument operation, result interpretation, and testing capacity.

Complex Regulatory Approval and Validation Requirements

Strict regulatory standards and lengthy validation procedures increase development costs and delay the commercialization of new immunoassay products.

01

Food Safety Testing Applications

Food testing laboratories and diagnostic manufacturers can use immunoassay-based solutions to detect allergens, mycotoxins, foodborne contaminants, and chemical residues. Dedicated testing kits can create opportunities across food processing, agriculture, and regulatory testing applications.

02

Immunoassay Services for Pharmaceutical Research

Contract research organizations and specialized laboratories can offer immunoassay-based services for drug development, biomarker validation, and pharmacokinetic studies. Revenue can come from outsourced analytical testing, assay development, and long-term research service contracts.

Immunoassay Market Segmentation

By Product

Reagents and kits dominated the product category with a share of 61.8% in 2025, owing to their extensive use in detecting and measuring specific biomarkers, hormones, and infectious agents. Their recurring use across diagnostic procedures and availability for different testing applications reinforce their leading position.

Software and services are expected to grow at a CAGR of 8.35% during the forecast period, driven by increasing need for laboratory automation, data management, and efficient interpretation of diagnostic results. Integration of specialized software and technical support services helps laboratories improve testing workflows.

Immunoassay Market Size By Segments

Request Customizationto receive a tailored report.

By Technology

ELISA dominated the technology category with a share of 44.5% in 2025, supported by its high sensitivity, reliable results, and ability to detect a wide range of antigens and antibodies. Its established use in infectious disease testing, hormone analysis, and clinical diagnostics reinforces its leading position.

Rapid tests are projected to register a CAGR of 8.65% over the forecast period, driven by increasing preference for quick diagnostic results and decentralized testing. Their ease of use and ability to deliver results without complex laboratory infrastructure support wider adoption.

By Specimen

Blood accounted for the largest share of the specimen category at 72.6% in 2025, owing to its extensive use in detecting antibodies, antigens, hormones, and disease-related biomarkers. Its suitability for a wide range of immunoassay procedures supports its dominant position.

Saliva is expected to grow at a CAGR of 8.75% throughout the forecast period, fueled by increasing interest in non-invasive sample collection and convenient diagnostic procedures. Its ease of collection and suitability for detecting certain hormones, antibodies, and biomarkers support its use in diagnostic testing.

By Application

Infectious diseases dominated the application category with a share of 31.8% in 2025, supported by the widespread use of immunoassays to detect viral, bacterial, and other infectious agents. Their role in disease screening, diagnosis, and monitoring reinforces their leading position.

Oncology applications are expected to grow at a CAGR of 9.15% during the forecast period, driven by increasing use of biomarker-based testing for cancer detection, diagnosis, and treatment monitoring. The role of immunoassays in identifying tumor markers and supporting clinical decisions further encourages adoption.

By End User

Hospitals held the largest share of the end-user category at 34.8% in 2025, owing to their high volume of diagnostic procedures and extensive use of immunoassay testing across multiple departments. Their access to advanced laboratory infrastructure and trained healthcare professionals supports their leading position.

Home care settings are projected to register a CAGR of 9.05% over the forecast period, fueled by increasing interest in convenient and decentralized diagnostic testing. The availability of rapid testing solutions and the preference for monitoring certain health conditions outside traditional healthcare facilities support adoption.

Immunoassay Market Share By Segments

Speak to an Analystto discuss market opportunities.

Immunoassay Regional Analysis

North America Immunoassay Market Analysis

The North America immunoassay market accounted for a dominant share of 39.5% in 2025.

U.S. Immunoassay Market

The U.S. recorded an important immunoassay development in August 2026, when the FDA cleared Roche's Elecsys pTau217 plasma blood test to support the assessment of amyloid pathology associated with Alzheimer's disease. The test uses immunoassay technology and can be used across primary and specialty care settings, supporting wider access to blood-based diagnostic testing.

Canada Immunoassay Market

Canada has an established clinical laboratory and diagnostic testing network that supports immunoassay applications in hospitals, diagnostic laboratories, and specialized healthcare facilities. These tests are used to detect hormones, infectious disease markers, cardiac biomarkers, and other substances in blood samples. Automated immunoassay analyzers and reagent-based testing support routine diagnostic workflows.

North America Immunoassay Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific immunoassay market

The Asia Pacific immunoassay market is expected to grow at a CAGR of 9.35% during the forecast period, showcasing the fastest-growing regional market.

China Immunoassay Market

China's healthcare system uses immunoassay-based testing across hospitals, clinical laboratories, and disease screening facilities. Applications include infectious disease detection, hormone analysis, tumor marker testing, and cardiac biomarker assessment. The country's broader diagnostic infrastructure and development of domestic in-vitro diagnostic technologies support the availability of immunoassay testing.

Japan Immunoassay Market

Japan has an advanced clinical diagnostics industry, with immunoassay technologies used for routine laboratory testing, disease monitoring, and specialized medical investigations. Automated platforms support the measurement of thyroid hormones, tumor markers, cardiac biomarkers, and infectious disease indicators, particularly in hospitals and centralized laboratories.

India Immunoassay Market

India strengthened its in-vitro diagnostic regulatory framework in 2026 through several initiatives by the Central Drugs Standard Control Organization (CDSCO). These included draft manufacturing guidance, updated laboratory performance evaluation information, and proposed evaluation protocols for diagnostic devices. Such measures are relevant to immunoassay kits and analyzers because they support product performance assessment, quality control, and regulatory oversight.

Europe immunoassay market

The Europe immunoassay market is expected to grow at a CAGR of 7.25% during the forecast period.

U.K. Immunoassay Market

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) established an in-vitro diagnostic roadmap covering 2026 and 2027. The roadmap focuses on regulatory support for innovative diagnostic technologies, research standards, and improved access to diagnostic devices. These priorities are relevant to immunoassay developers working on advanced biomarker detection and companion diagnostic applications.

Germany Immunoassay Market

Germany has a well-developed clinical laboratory network, where immunoassays are used for infectious disease screening, hormone testing, allergy assessment, and cancer biomarker analysis. Hospitals and independent diagnostic laboratories use automated immunoassay systems to process routine and specialized tests, supporting clinical diagnosis and treatment monitoring.

Competitive Landscape

The immunoassay market is moderately consolidated, with a mix of medical diagnostics manufacturers, clinical laboratory equipment providers, biotechnology companies, and specialized diagnostic testing solution providers. Key players such as Abbott Laboratories, Hoffmann-La Roche, Siemens Healthineers, Danaher Corporation, and Thermo Fisher Scientific account for an estimated 45–55% of the global immunoassay market share in 2025.

Established players compete through assay accuracy, testing speed, automation capabilities, product reliability, extensive diagnostic portfolios, and global distribution networks. Emerging and specialized players compete through innovative testing technologies, cost-effective diagnostic solutions, specialized assay development, compact testing platforms, and customized solutions for clinical laboratories and point-of-care applications within the immunoassay market ecosystem.

List of Key and Emerging Players in Immunoassay Market

Abbott Laboratories (U.S.)
F. Hoffmann-La Roche AG (Switzerland)
Siemens Healthineers AG (Germany)
Danaher Corporation (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
bioMérieux SA (France)
QuidelOrtho Corporation (U.S.)
Becton, Dickinson and Company (U.S.)
Bio-Rad Laboratories, Inc. (U.S.)
Revvity, Inc. (U.S.)
Sysmex Corporation (Japan)
Agilent Technologies, Inc. (U.S.)
Merck KGaA (Germany)
DiaSorin S.p.A. (Italy)
Mindray Bio-Medical Electronics Co., Ltd. (China)

Key Industry Developments

March 2026
Roche expanded its immunoassay diagnostics portfolio with new laboratory testing solutions designed to improve automation, accuracy, and efficiency in clinical diagnostics.
September 2025
Abbott introduced enhanced immunoassay technologies for its diagnostic platforms, supporting faster and more reliable testing across infectious diseases, cardiology, and other clinical applications.
May 2025
Siemens Healthineers expanded its immunoassay testing capabilities with upgraded laboratory diagnostic solutions focused on improved workflow automation and patient testing efficiency.

Report Scope

Segmentation

By Product 3
  • Reagents & Kits
  • Analyzer
  • Software and Services
By Technology 5
  • ELISA
  • Rapid Tests
  • Western Blotting
  • Radioimmunoassay
  • Other technologies
By Specimen 4
  • Blood
  • Saliva
  • Urine
  • Other Specimen
By Application 10
  • Infectious diseases
  • Endocrinology
  • Oncology
  • Bone and mineral disorders
  • Cardiology
  • Blood screening
  • Autoimmune Disorders
  • Allergy Diagnostics
  • Toxicology
  • Other Application
By End-User 7
  • Hospitals
  • Clinical Laboratories
  • Pharmaceutical & Biotechnology Companies and CRO
  • Blood Banks
  • Research & Academic Laboratories
  • Home Care Setting
  • Others

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 7
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage Abbott Laboratories (U.S.) · F. Hoffmann-La Roche AG (Switzerland) · Siemens Healthineers AG (Germany) · Danaher Corporation (U.S.) · Thermo Fisher Scientific Inc. (U.S.)
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Reportto Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The immunoassay market size is valued at USD 29.60 Billion in 2026 and is projected to reach USD 42.55 Billion by 2034, at a CAGR of 4.64% during the forecast period 2026–2034.
North America dominated the market with a share of 39.5% in 2025.
The leading players in this market are Abbott Laboratories, Hoffmann-La Roche Ltd., Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific Inc..
The immunoassay market is projected to grow at a CAGR of 4.64% during the forecast period of 2026 2034.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
Trusted by Industry Leaders
LG ElectronicsAMCAD EngineeringKOBE STEEL LTD.Hindustan National Glass & Industries LimitedVoith GroupInternational PaperHansol PaperWhirlpool CorporationSonySamsung ElectronicsQualcommGoogleFiservVeto-PharmaNippon Becton DickinsonMerckArgon Medical DevicesAbbottAjinomotoDenonDoosanMeiji Seika Kaisha LtdLG ChemicalsLCY chemical groupBayerAirraneBASFToyota IndustriesNissan MotorsNeenahMitsubishiHyundai Motor CompanyHondaCRP Industries IncpewagLGEPanasonicLubrizol CorporationLeonardoJohnson & JohnsonHB FullerMITSUBISHI CHEMICALHyundai MobisAmazon
Request SampleOrder Report Now